BackgroundPrimary ductal adenocarcinomas of the lacrimal gland are very rare. This neoplasm shares some histological and immunohistochemical similarities with salivary duct carcinoma.Case presentationHere, we present a case of a 55-year-old Moroccan man with lacrimal gland adenocarcinoma. He underwent orbital exenteration with lymph nodes dissection and ipsilateral parotidectomy. After surgery, he was lost to follow-up and died 13 months later.ConclusionsLacrimal gland tumors are rare but highly aggressive salivary gland tumors. Complete excision with adjuvant radiotherapy is recommended.
Background: Squamous cell carcinoma of the rectum is a distinct entity. We report a rare case of squamous cell carcinoma of the middle and low rectum. Case presentation: The patient was a 60-year-old man who presented with a history of rectal Bleeding, constipation and pelvic painless. Rectoscopy and Colonoscopy revealed a polypoid tumour of the middle and low rectum. Biopsies of this mass revealed a poorly differentiated squamous cell carcinoma of the rectum. Pelvic Magnetic Resonance Imaging scan showed a polypoid, irregular and circumferential tumor in the middle and low rectum extending in length on 95mm. CT scan of the chest, abdomen and pelvis was negative for distal metastases. The patient received combined chemo-radiation. Overall treatment time was 45 days. After 6 weeks of the end of treatment, the revaluation clinical tests by pelvic magnetic resonnance imaging showed a poor response. After 3 months, Positron Emission Tomography with Fluorodeoxyglucose demonstrated a little hypermetabolic area with maximum standard up take value of 6,7 in the low rectum. Patient underwent a surgical resection. The postoperative histopathological findings were non specific and chronic inflammatory changes. At the time this report was written, the patient had 18 months of follow-up. No evidence of malignacy is found. Conclusion: Squamous cell carcinoma of the rectum is a distinct entity. Chemoradiation should be chosen as the first-line therapy for suqamous cell carcinoma of the rectum. However,a large study will be required to establish a safe and effective regimen.
Background: Overall treatment time is an important factor in the outcome of cervix cancer treatment. However, in daily clinical practice, unplanned treatment interruptions are inevitable for many reasons. We performed a prospective study to assess the overall treatment time for patients treated in our department and identify the causes of treatment prolongation. Material and methods: Between first January and 30 April 2016, a group of patients with locally advanced cervix cancer was interviewed at the end of treatment. Data was collected using a questionnaire containing important study parameters. Results: 100 patients were interviewed. The mean age of women was 55,08 ± 12,43 years. Seventy-five patients (75%) were illiterate. Ninety-six patients (96%) has low socio-economic level. Ninety patients (90%) has squamous cell carcinoma. The stage IIIB represented the majority of cases (90%). All patients were treated with concurrent chemoradiation except one patient. Pelvic radiation at the dose of 46 Gy was performed for all patients. The median time to complete pelvis RT was 37 days (34-42 days). Only seventy-seven patients (77%) were treated by BT. A median time of the first brachytherapy insertion was 13,50 days (0-20 days). The median of OTT was 71 days (64-78 days). This prolongation was mainly due to the delay of the first brachytherapy insertion. In the univariate and multivariate analysis, 2 factors were associated with longer overall treatment time: age (p=0,006) and stage (p=0,001). Conclusion: In our country, cervical cancer outcomes are still poor. To improve the prognosis, overall treatment time should be given in timely manner (8weeks).
BackgroundGastric cancer is the second leading cause of cancer related death among men and the fourth among women, and thus represents a significant global health concern [1]. The disease is commonly diagnosed at a locally advanced stage, and surgery remains the main treatment; The overall survival rate of patients who underwent surgery alone is about 45% at 5 years, that has undergone few changes over the last decades [2,3].The curative treatment of gastric cancer requires surgical resection in less than 40% of cases [2,3]. Independent risk factors in the literature are tumor size (>4 cm), age (>70 years), proximal location, diffuse type of Lauren classification, tumor residue, Deep invasion (T3-T4), and the ratio of involved lymph nodes/total number (>20%) [4,5]. Locoregional recurrences on the tumor bed, on the anastomosis or in lymph nodes occur in 40% to 65% of the patients after resection with curative intent [6,7]. The frequency of this relapse makes regional radiotherapy an attractive possibility for adjuvant therapy [8].Various chemotherapy regimens used to prevent relapse and improve the poor survival rates provide small but statistically significant clinical benefit [9,10]. Finally, the intergroup of gastrointestinal cancers was the first to demonstrate in a phase III trial that concomitant radio-chemotherapy after complete gastric resection improves median relapse-free survival (30 vs 19 months, p<0.0001) and overall survival (36 vs 27 months, p<0.01) [11]. Following these results, postoperative radio-chemotherapy according to the Macdonald protocol became the new standard of care [11]. However, much concern remains regarding the toxicity of the regimen. 41% of patients had grade 3 digestive toxicity and 32% grade 4 [11]. The objective of our AbstractBackground: Several studies have shown that surgery alone is not enough in the management of early gastric cancer with locoregional relapse in 40% to 60%. The frequency of relapses makes regional radiotherapy an attractive possibility for adjuvant therapy. The survival benefit of adjuvant chemoradiation over surgery alone was first established by the US Intergroup 0116 study.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.